-

DeFi Technologies Inc. (DEFT) Shareholders Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP:

DeFi Technologies Inc. (NASDAQ: DEFT), formerly known as Valour Inc., purports to be a technology and digital asset treasury (“DAT”) company that develops exchange traded products in Canada

Share

What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired DeFi Technologies Inc. during the class period because the Company allegedly misled investors regarding its business prospects.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Company: DeFi Technologies Inc. (NASDAQ: DEFT), formerly known as Valour Inc., purports to be a technology and digital asset treasury (“DAT”) company that develops exchange traded products in Canada that synthetically track the value of a single decentralized finance (“DeFi”) protocol—that is, a set of standards and rules that govern a system of lending, borrowing, and trading a cryptocurrency—or a basket of DeFi protocols.

What is the class period? May 12, 2025 – November 14, 2025

What are the allegations? According to the complaint, defendants failed to disclose that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; and (iv) accordingly, defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies’ business and financial result.

Plaintiff alleges that on November 14, 2025, DeFi Technologies issued a press release reporting disappointing financial results for the third quarter of 2025. Among other items, DeFi Technologies reported a revenue decline of nearly 20%, falling well short of market expectations. The Company also significantly lowered its 2025 revenue forecast, from $218.6 million to approximately $116.6 million, and attributed this reduction to “a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025.” Concurrently, DeFi Technologies announced that Defendant Newton would leave his role as CEO and assume an advisory position. Following these disclosures, DeFi Technologies’ stock price fell $0.40 per share, or 27.59%, over the following two trading sessions, to close at $1.05 per share on November 17, 2025

What can you do now? You may be eligible to participate in the class action against DeFi Technologies Inc. Shareholders, who wish to serve as lead plaintiff for the class must submit their papers with the court by January 30, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against DeFi Technologies Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:DEFT

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Reminds Intuit Inc. Investors With Significant Losses of the Opportunity to Lead the the Securities Fraud Class Action Against INTU

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Intuit Inc. (NASDAQ: INTU ) securities between August 22, 2025 and May 20, 2026, inclusive (the “Class Period”).The lawsuit alleges that Intuit misled investors about the sustainability and growth of its business, including its TurboTax business, and failed to disclose increasing competitive and pricing pressures affecti...

Investor Alert: Robbins LLP Informs Investors of the Wise Group plc Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom